Xlife Sciences AGXSWX:XLS +0.83%53 Equity-to-Asset is 0.55 as of Dec. 2025, which is 2% below its 10-year median of 0.56. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.22 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,416 Biotechnology companies, Xlife Sciences AG ranks worse than 63.63% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Xlife Sciences AG's Total Stockholders Equity for the quarter that ended in Dec. 2025 was CHF286.53 Mil. Xlife Sciences AG's Total Assets for the quarter that ended in Dec. 2025 was CHF517.12 Mil.
Therefore, Xlife Sciences AG's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.55.
The historical rank and industry rank for Xlife Sciences AG's Equity-to-Asset or its related term are showing as below:
XSWX:XLS'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44 Med: 0.56 Max: 0.7
Current: 0.55
During the past 8 years, the highest Equity to Asset Ratio of Xlife Sciences AG was 0.70. The lowest was 0.44. And the median was 0.56.
XSWX:XLS's Equity-to-Asset is ranked worse than 63.63% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs XSWX:XLS: 0.55
Xlife Sciences AG (XSWX:XLS) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Xlife Sciences AG Equity-to-Asset Related Terms
Xlife Sciences AG Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Xlife Sciences AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a Equity-to-Asset of 0.55 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Xlife Sciences AG and its competitors. This is near median its historical median of 0.56. Over the past decade, Xlife Sciences AG's Equity-to-Asset has ranged from 0.44 to 0.70. According to the industry distribution chart, Xlife Sciences AG ranks #901 out of 1416 companies in the Biotechnology industry, placing it in the top 63.6%.
Is Xlife Sciences AG's Equity-to-Asset too high?
Xlife Sciences AG's current Equity-to-Asset of 0.55 is near median its 10-year median of 0.56. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 0.70. The Biotechnology industry median Equity-to-Asset is 0.68. Xlife Sciences AG's value of 0.55 is 19.1% below this industry median. Based on the distribution chart, Xlife Sciences AG ranks #901 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #901 out of 1416 companies for Equity-to-Asset. This places Xlife Sciences AG in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Xlife Sciences AG's value of 0.55 is 19.1% below this benchmark. Historically, Xlife Sciences AG's own Equity-to-Asset has ranged from 0.44 to 0.70 over the past decade. While the company's 10-year median is 0.56 vs. the industry median of 0.68, Xlife Sciences AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current Equity-to-Asset of 0.55 is 19.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Equity-to-Asset is 0.55, which is near median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.22, compared to a current price of CHF18.15 — trading 151.4% above its estimated fair value. The current Equity-to-Asset is 0.55, which is near median its 10-year median of 0.56 and 19.1% below the Biotechnology industry median of 0.68. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Equity-to-Asset is 0.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF18.15 is trading 151.4% above its estimated GF Value™ of CHF7.22.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Equity-to-Asset: 0.55 (near median its 10-year median of 0.56)
GF Value™: CHF7.22 vs. price of CHF18.15 (151.4% above fair value)
Industry Position: 19.1% below the Biotechnology median (#901 of 1416)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score
Get the complete analysis for XSWX:XLS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
